[go: up one dir, main page]

BRPI0017528B8 - uso de uma composição contendo sal de cetotifeno - Google Patents

uso de uma composição contendo sal de cetotifeno

Info

Publication number
BRPI0017528B8
BRPI0017528B8 BRPI0017528A BRPI0017528A BRPI0017528B8 BR PI0017528 B8 BRPI0017528 B8 BR PI0017528B8 BR PI0017528 A BRPI0017528 A BR PI0017528A BR PI0017528 A BRPI0017528 A BR PI0017528A BR PI0017528 B8 BRPI0017528 B8 BR PI0017528B8
Authority
BR
Brazil
Prior art keywords
composition containing
containing ketotifen
ketotifen salt
salt
active agent
Prior art date
Application number
BRPI0017528A
Other languages
English (en)
Inventor
Andrea Fetz
Gyorgy Lajos Kis
Marcia Johanna Adam
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0017528A2 publication Critical patent/BRPI0017528A2/pt
Publication of BRPI0017528B1 publication Critical patent/BRPI0017528B1/pt
Publication of BRPI0017528B8 publication Critical patent/BRPI0017528B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de uma composição contendo sal de cetotifeno. a presente invenção refere-se ao uso de uma composição oftálmica contendo cetotifeno como um agente farmaceuticamente ativo.
BRPI0017528A 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno BRPI0017528B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99114508 1999-07-23
EP99114508.7 1999-07-23
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica
PCT/EP2000/007030 WO2001007049A2 (en) 1999-07-23 2000-07-21 Ophthalmic composition comprising ketotifen

Publications (3)

Publication Number Publication Date
BRPI0017528A2 BRPI0017528A2 (pt) 2010-01-19
BRPI0017528B1 BRPI0017528B1 (pt) 2017-06-13
BRPI0017528B8 true BRPI0017528B8 (pt) 2021-05-25

Family

ID=8238654

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica
BRPI0017528A BRPI0017528B8 (pt) 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica

Country Status (20)

Country Link
US (2) US6777429B1 (pt)
EP (1) EP1198223A2 (pt)
JP (1) JP2003505419A (pt)
KR (1) KR20020012261A (pt)
CN (1) CN1358086A (pt)
BR (2) BR0012696A (pt)
CA (1) CA2377024A1 (pt)
CZ (1) CZ300614B6 (pt)
EE (1) EE05439B1 (pt)
HK (1) HK1046631A1 (pt)
HU (1) HU230738B1 (pt)
IL (1) IL146973A0 (pt)
MX (1) MXPA02000849A (pt)
NO (1) NO331228B1 (pt)
NZ (1) NZ516108A (pt)
PL (1) PL202496B1 (pt)
RU (1) RU2248789C2 (pt)
UA (1) UA74788C2 (pt)
WO (1) WO2001007049A2 (pt)
ZA (1) ZA200200425B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2002100436A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic once-a-day composition
KR20120035220A (ko) * 2003-01-22 2012-04-13 센주 세이야꾸 가부시키가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환 치료약의 눈의 국소 조직으로의 이행 방법
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
ATE463244T1 (de) * 2004-10-25 2010-04-15 Bausch & Lomb Ophthalmische zusammensetzungen und verfahren zu deren verwendung
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
HUE018715T2 (hu) 2006-06-16 2024-10-28 Regeneron Pharma Intravitreális beadásra alkalmas VEGF antagonista készítmények
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
EP2471509B1 (en) * 2006-09-29 2017-04-19 Johnson & Johnson Vision Care, Inc. Method of preventing oxidation of an ophthalmic device comprising an anti-allergic agent
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
JP5460600B2 (ja) * 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
CA3179836A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
RU2003350C1 (ru) * 1991-03-01 1993-11-30 Институт иммунологии Способ лечени глюкокортикостероидзависимых атопических заболеваний
RU2007117C1 (ru) * 1992-03-20 1994-02-15 Юлия Михайловна Залесская Способ индивидуального подбора веществ для коррекции нарушений в организме
EP0694310B1 (en) * 1993-04-16 2000-02-16 Wakamoto Pharmaceutical Co., Ltd. Reversible, thermally gelling water-base medicinal composition
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent

Also Published As

Publication number Publication date
ZA200200425B (en) 2002-10-30
EP1198223A2 (en) 2002-04-24
WO2001007049A2 (en) 2001-02-01
CZ2002243A3 (cs) 2002-04-17
UA74788C2 (en) 2006-02-15
HU230738B1 (hu) 2018-01-29
BRPI0017528B1 (pt) 2017-06-13
NO20020319L (no) 2002-01-21
US6777429B1 (en) 2004-08-17
MXPA02000849A (es) 2002-07-30
EE200200040A (et) 2003-04-15
NO20020319D0 (no) 2002-01-21
RU2248789C2 (ru) 2005-03-27
CA2377024A1 (en) 2001-02-01
EE05439B1 (et) 2011-08-15
WO2001007049A3 (en) 2001-03-29
NZ516108A (en) 2004-04-30
PL352382A1 (en) 2003-08-25
BR0012696A (pt) 2002-04-09
HUP0202243A2 (hu) 2002-12-28
IL146973A0 (en) 2002-08-14
NO331228B1 (no) 2011-11-07
JP2003505419A (ja) 2003-02-12
US20020183359A1 (en) 2002-12-05
US6774137B2 (en) 2004-08-10
BRPI0017528A2 (pt) 2010-01-19
CN1358086A (zh) 2002-07-10
KR20020012261A (ko) 2002-02-15
PL202496B1 (pl) 2009-06-30
CZ300614B6 (cs) 2009-07-01
HK1046631A1 (zh) 2003-01-24
HUP0202243A3 (en) 2006-03-28

Similar Documents

Publication Publication Date Title
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
NZ597106A (en) Ophthalmic compositions comprising carnitine and methods for treating eyes
YU40701A (sh) Piperidini kao modulatori ccr5
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
DE69921318D1 (de) Tensid für äusserlich anzuwendende hautpräparate und diese beinhaltende äusserlich anzuwendende hautpräparate
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
BR0210013A (pt) Gel oftálmico de pirenzepina
BR0111678A (pt) Composições medicinais contendo derivados de propenona
SE9901077D0 (sv) Novel use
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BRPI0403461A (pt) composições estabilizadas contendo um agente ativo lábil ao oxigênio
ES2171669T3 (es) Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.
BR0009194A (pt) Composição do resorcinol
ES2161913T3 (es) Complejos cationicos trinucleares de platino que tienen una actividad antitumoral y composiciones farmaceuticas que los contienen.
HN2000000090A (es) Sal difosfato de un derivado de 4sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica.
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
AR016200A1 (es) El uso de una composicion que comprende uno o mas compuestos que contienen azufre para la fabricacion de un medicamento para aumentar la permeabilidad deltejido corneo humano, y un kit que incluye dicha composicion
AR023374A1 (es) Derivados de 3-amino-3-arilpropano-1-ol. su preparacion y uso
DK0802920T3 (da) Fusacandin-antisvampemidler

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/07/2020